Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Merck & Co., Inc. (MRK) Market Cap & Valuation Ratios

Merck & Co., Inc. (MRK) has a market cap of $358.4B, a trailing P/E of 115.3 and a price-to-sales ratio of 5.4, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

MRKMerck & Co., Inc.Follow MRK — free
Drug Manufacturers - General · Healthcare
—
Price chart with a free account
Market cap
358.4B
P/E TTM
115.3
Dividend yield
2.3%
52-week
—
Next earnings
29 Oct, in 5 days

Peers

drug manufacturers - general · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
MRK358115.36.128.14.5%+5%12%5%
LLY119942.715.643.51.5%+50%41%27%
JNJ63540.06.724.73.2%+8%19%16%
ABBV50580.78.823.03.6%+10%26%21%
AZN27425.74.914.74.3%+9%23%16%
AMGN23727.37.417.44.3%+9%30%18%
GILD193—7.1823.46.7%+6%-8%-7%
PFE17139.53.516.86.4%-0.2%11%4%
BMY12613.53.29.49.1%+3%28%19%
TEVA46—3.422.72.9%+4%9%7%
ONC4367.66.536.93.1%+34%15%35%
Median of these 1039.86.622.83.9%+8%21%17%

P/E 115.3 vs. a peer median of 39.8; EV/Sales 6.1 vs. 6.6. MRK's own P/E sits at the 87th percentile of its history.

Growth vs. price

each dot a company · hover or tap for values
1020501000%+10%+20%+30%+40%+50%revenue growth, TTM →P/E (log)MRKLLYJNJABBVAZNAMGNPFEBMYONC

GILD and TEVA have no P/E (earnings not positive) and are left out · hover or tap a dot for values.

Merck & Co., Inc. — questions

What is Merck & Co., Inc.'s market cap?
$358.4B.
What is Merck & Co., Inc.'s P/E ratio?
115.3 on trailing twelve-month earnings to 2026-06-30.
What is Merck & Co., Inc.'s price-to-sales ratio?
5.4.

Every figure on this page comes from Merck & Co., Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.